“…A biomarker is a measurable characteristic indicating normal or pathogenic biological processes or pharmacological responses to therapeutic drugs (Miglis et al., 2021 ). Biomarkers used for diagnosis of iRBD patients include neurophysiological (polysomnography, actigraphy, electroencephalogram), clinical (hyposmia, cognitive dysfunction, visual dysfunction, motor function, autonomic function) and biological biomarker (blood test, CSF, tissue biopsy), neuroimaging (positron emission tomography [PET], single‐photon emission computed tomography [SPECT], structural magnetic resonance imaging [MRI], DWI and fMRI), and genetic biomarker (GBA variants, SNCA, TMEM175) (Bramich et al., 2022 ; Gnarra et al., 2023 ; Zhang et al., 2023 ).…”